Expression of Eukaryotic initiation factor 5A and Hypusine forming enzymes in glioblastoma patient samples: Implications for new targeted therapies

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Preukschas, Michael ^a   Hagel, Christian ^a   Schulte, Alexander ^a   Weber, Kristoffer ^a   Lamszus, Katrin ^a   Sievert, Henning ^a   Pällmann, Nora ^a   Bokemeyer, Carsten ^a   Hauber, Joachim ^b   Braig, Melanie ^a   Balabanov, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; DEOXYHYPUSINE HYDROXYLASE; DEOXYHYPUSINE SYNTHASE; DEOXYHYPUSINE SYNTHASE INHIBITOR; ENZYME INHIBITOR; HYPUSINE; INITIATION FACTOR 5A; N1 GUANYL 1,7 DIAMINOHEPTANE; OXYGENASE; PROTEIN P53; SHORT HAIRPIN RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARMUSTINE; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; GUANINE; HUMANS; LYSINE; MALE; MIXED FUNCTION OXYGENASES; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PEPTIDE INITIATION FACTORS; RNA-BINDING PROTEINS;

EID: 84865191408     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043468     Document Type: Article

References (65)

1. Wen PY, Kesari S, (2008) Malignant gliomas in adults. The New England Journal of Medicine 359: 492-507.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 352: 987-996.
3. Noda S-e, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, et al. (2009) Molecular advances of brain tumors in radiation oncology. Seminars in Radiation Oncology 19: 171-178.
4. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine 352: 997-1003.
5. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
6. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 321: 1807-1812.
7. Van Meir EG (2009) CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches: Springer.
8. Van Meir EG, Hadjipanayis CG, Norden AD, Shu H-K, Wen PY, et al. (2010) Exciting New Advances in Neuro-Oncology. CA: a cancer journal for clinicians 60: 166-193.
9. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, et al. (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology 96: 219-230.
10. Wick W, Weller M, van den Bent M, Stupp R, (2010) Bevacizumab and Recurrent Malignant Gliomas: A European Perspective. Journal of Clinical Oncology 28: e188-e189.
11. Shiba T, Mizote H, Kaneko T, Nakajima T, Kakimoto Y, (1971) Hypusine, a new amino acid occurring in bovine brain. Isolation and structural determination. Biochimica Et Biophysica Acta 244: 523-531.
12. Cooper HL, Park MH, Folk JE, (1982) Posttranslational formation of hypusine in a single major protein occurs generally in growing cells and is associated with activation of lymphocyte growth. Cell 29: 791-797.
13. Abbruzzese A, Park MH, Folk JE, (1986) Deoxyhypusine hydroxylase from rat testis. Partial purification and characterization. The Journal of Biological Chemistry 261: 3085-3089.
14. Park MH, Cooper HL, Folk JE, (1981) Identification of hypusine, an unusual amino acid, in a protein from human lymphocytes and of spermidine as its biosynthetic precursor. Proceedings of the National Academy of Sciences of the United States of America 78: 2869-2873.
15. Jenkins ZA, Hååg PG, Johansson HE, (2001) Human EIF5A2 on Chromosome 3q25-q27 Is a Phylogenetically Conserved Vertebrate Variant of Eukaryotic Translation Initiation Factor 5A with Tissue-Specific Expression. Genomics 71: 101-109.
16. Kyrpides NC, Woese CR, (1998) Universally conserved translation initiation factors. Proceedings of the National Academy of Sciences of the United States of America 95: 224-228.
17. Schnier J, Schwelberger HG, Smit-McBride Z, Kang HA, Hershey JW, (1991) Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Molecular and Cellular Biology 11: 3105-3114.
18. Nishimura K, Lee SB, Park JH, Park MH, (2012) Essential role of eIF5A-1 and deoxyhypusine synthase in mouse embryonic development. Amino Acids 42: 703-710.
19. Templin AT, Maier B, Nishiki Y, Tersey SA, Mirmira RG, (2011) Deoxyhypusine synthase haploinsufficiency attenuates acute cytokine signaling. Cell Cycle 10: 1043-1049.
20. Benne R, Brown-Luedi ML, Hershey JW, (1978) Purification and characterization of protein synthesis initiation factors eIF-1, eIF-4C, eIF-4D, and eIF-5 from rabbit reticulocytes. The Journal of Biological Chemistry 253: 3070-3077.
21. Zuk D, Jacobson A, (1998) A single amino acid substitution in yeast eIF-5A results in mRNA stabilization. The EMBO Journal 17: 2914-2925.
22. Caraglia M, Marra M, Giuberti G, D'Alessandro AM, Budillon A, et al. (2001) The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino acids 20: 91-104.
23. Caraglia M, Park MH, Wolff EC, Marra M, Abbruzzese A (2011) eIF5A isoforms and cancer: two brothers for two functions? Amino Acids [Epub ahead of print]: 1-7.
24. Tome ME, Fiser SM, Payne CM, Gerner EW, (1997) Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. The Biochemical Journal 328 (Pt 3): 847-854.
25. Tome ME, Gerner EW, (1997) Cellular eukaryotic initiation factor 5A content as a mediator of polyamine effects on growth and apoptosis. Biological signals 6: 150-156.
26. Caraglia M, Passeggio A, Beninati S, Leardi A, Nicolini L, et al. (1997) Interferon a2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. BIOCHEMICAL JOURNAL-LONDON- 324: 737-741.
27. Caraglia M, Marra M, Giuberti G, D'Alessandro AM, Baldi A, et al. (2003) The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. Journal of biochemistry 133: 757-765.
28. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109: 1701-1711.
29. Lam F, Jankova L, Dent OF, Molloy MP, Kwun SY, et al. (2010) Identification of distinctive protein expression patterns in colorectal adenoma. Proteomics Clinical Applications 4: 60-70.
30. Yang G-F, Xie D, Liu J-H, Luo J-H, Li L-J, et al. (2009) Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecologic Oncology 112: 314-318.
31. Chen W, Luo J-H, Hua W-F, Zhou F-J, Lin MC, et al. (2009) Overexpression of EIF-5A2 Is an Independent Predictor of Outcome in Patients of Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Cancer Epidemiol Biomarkers Prev 18: 400-408.
32. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, et al. (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-864.
33. He L-R, Zhao H-Y, Li B-K, Liu Y-H, Liu M-Z, et al. (2011) Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. International Journal of Cancer 129: 143-150.
34. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, et al. (2009) Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. International Journal of Cancer 9999: NA.
35. Lu ZJ, Liu SY, Yao YQ, Zhou YJ, Zhang S, et al. (2011) The effect of miR-7 on behavior and global protein expression in glioma cell lines. Electrophoresis 32: 3612-3620.
36. Kunkel P, Müller S, Schirmacher P, Stavrou D, Fillbrandt R, et al. (2001) Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-Oncology 3: 82-88.
37. Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, et al. (2009) RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. Journal of Neurochemistry 109: 969-980.
38. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29: e45.
39. Klier H, Csonga R, Joäo HC, Eckerskorn C, Auer M, et al. (1995) Isolation and structural characterization of different isoforms of the hypusine-containing protein eIF-5A from HeLa cells. Biochemistry 34: 14693-14702.
40. Wolff EC, Lee SB, Park MH, (2011) Assay of deoxyhypusine synthase activity. Methods in Molecular Biology (Clifton, NJ) 720: 195-205.
41. Beyer WR, Westphal M, Ostertag W, von Laer D, (2002) Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range. J Virol 76: 1488-1495.
42. Weber K, Bartsch U, Stocking C, Fehse B, (2008) A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Molecular therapy: the journal of the American Society of Gene Therapy 16: 698-706.
43. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, et al. (2011) Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell death & disease 2: e243.
44. Weber K, Mock U, Petrowitz B, Bartsch U, Fehse B, (2010) Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene therapy 17: 511-520.
45. Riccardi C, Nicoletti I, (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protocols 1: 1458-1461.
46. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. (2002) A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy. Cell 109: 335-346.
47. Jakus J, Wolff EC, Park MH, Folk JE, (1993) Features of the spermidine-binding site of deoxyhypusine synthase as derived from inhibition studies. Effective inhibition by bis- and mono-guanylated diamines and polyamines. The Journal of Biological Chemistry 268: 13151-13159.
48. Wolff EC, Kang KR, Kim YS, Park MH, (2007) Posttranslational synthesis of hypusine: evolutionary progression and specificity of the hypusine modification. Amino Acids 33: 341-350.
49. Shi XP, Yin KC, Ahern J, Davis LJ, Stern AM, et al. (1996) Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochimica Et Biophysica Acta 1310: 119-126.
50. Taylor CA, Sun Z, Cliche DO, Ming H, Eshaque B, et al. (2007) Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. Experimental Cell Research 313: 437-449.
51. Chatterjee I, Gross SR, Kinzy TG, Chen KY, (2006) Rapid depletion of mutant eukaryotic initiation factor 5A at restrictive temperature reveals connections to actin cytoskeleton and cell cycle progression. Molecular Genetics and Genomics: MGG 275: 264-276.
52. Park MH, Joe YA, Kang KR, (1998) Deoxyhypusine synthase activity is essential for cell viability in the yeast Saccharomyces cerevisiae. The Journal of Biological Chemistry 273: 1677-1683.
53. Park MH, Wolff EC, Lee YB, Folk JE, (1994) Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. The Journal of Biological Chemistry 269: 27827-27832.
54. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, et al. (2002) Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1: 269-277.
55. Schmitt CA, (2003) Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 3: 286-295.
56. Brown JP, Wei W, Sedivy JM, (1997) Bypass of Senescence After Disruption of p21CIP1/WAF1 Gene in Normal Diploid Human Fibroblasts. Science 277: 831-834.
57. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathology (Zurich, Switzerland) 9: 469-479.
58. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, et al. (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biology 3: 245-252.
59. Li A-L, Li H-Y, Jin B-F, Ye Q-N, Zhou T, et al. (2004) A Novel eIF5A Complex Functions As a Regulator of p53 and p53-dependent Apoptosis. J Biol Chem 279: 49251-49258.
60. Rahman-Roblick R, Johannes Roblick U, Hellman U, Conrotto P, Liu T, et al. (2007) p53 targets identified by protein expression profiling. Proceedings of the National Academy of Sciences 104: 5401-5406.
61. Specht S, Sarite SR, Hauber I, Hauber J, Görbig UF, et al. (2008) The guanylhydrazone CNI-1493: an inhibitor with dual activity against malaria-inhibition of host cell pro-inflammatory cytokine release and parasitic deoxyhypusine synthase. Parasitology Research 102: 1177-1184.
62. Sun Z, Cheng Z, Taylor CA, McConkey BJ, Thompson JE, (2010) Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. Journal of Cellular Physiology 223: 798-809.
63. Hirose Y, Berger MS, Pieper RO, (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Research 61: 1957-1963.
64. Günther W, Pawlak E, Damasceno R, Arnold H, Terzis AJ, (2003) Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. British Journal of Cancer 88: 463-469.
65. Park MH, Nishimura K, Zanelli CF, Valentini SR, (2010) Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38: 491-500.